Notable Labs, Ltd.: Nasdaq/NYSE listing notice — VBLT receives Nasdaq delisting notice for bid price noncompliance; plans hearing

Notable Labs, Ltd.

Nasdaq notified VBLT on Aug 29, 2023 that it failed to regain minimum bid price compliance by Aug 28, 2023 deadline.
VBLT intends to request a hearing before Nasdaq Hearings Panel to stay suspension pending hearing outcome.
VBLT will argue that pending merger and reverse stock split will enable the combined company to meet Nasdaq initial listing requirements.
There can be no assurance the panel will grant the suspension or continued listing, or that the combined company will meet listing requirements.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Notable Labs, Ltd. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2), 5810(c)(3)(A)(ii)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5550(a)(2), 5810(c)(3)(A)(ii)

Exact text from the filing

August 29, 2023, VBL was notified by Nasdaq that it had not regained compliance with the Minimum Bid Price Requirement. VBL intends to timely request a hearing before the Nasdaq Hearings Panel (the “Panel”), which will stay the suspension of VBL’s ordinary shares pending the Panel’s conclusion of the hearing process. VBL intends to request the extension to regain compliance on the basis that completion of the pending merger transaction and reverse stock split, as described in the amended registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission on September 1, 2

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-031501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.